Format

Send to

Choose Destination
See comment in PubMed Commons below
Biochem Pharmacol. 2012 Dec 1;84(11):1388-99. doi: 10.1016/j.bcp.2012.07.031. Epub 2012 Aug 4.

Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer.

Author information

1
Pharmaceutical Department, University of Parma, Italy. caterina.carmi@unipr.it

Abstract

Irreversible inhibitors provide potent and selective inhibition of tyrosine kinase enzymes. Use of such inhibitors has proved promising in overcoming the tumor resistance encountered with reversible tyrosine kinase inhibitors. Irreversible inhibitors inactivate their protein target through covalent interaction with a nucleophilic cysteine residue within the nucleotide binding pocket of the kinase domain. Different irreversible tyrosin kinase inhibitors directed against epidermal growth factor receptor (EGFR), Bruton's tyrosine kinase (BTK), vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor tyrosine kinase (FGFR) have been developed and some of them have been employed clinically as anticancer agents. This review focuses on recent preclinical and clinical progress with currently available irreversible tyrosine kinase inhibitors. The chemical structures of the candidates, structure-activity relationships, biological activities and results of current clinical investigations are described.

PMID:
22885287
DOI:
10.1016/j.bcp.2012.07.031
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center